Sign in Subscribe
Diseases

Immune Checkpoint Inhibitors and Chronic Obstructive Pulmonary Disease: A Complex Relationship

Strategic Insights

— 1 min read

Research published in Current Oncology suggests that immune checkpoint inhibitors (ICIs) are a common treatment option for non-small cell lung cancer (NSCLC), but may pose a risk of potentially life-threatening immune-related adverse events, including checkpoint inhibitor pneumonitis (CIP). A study conducted at the Jewish General Hospital in Montreal, Canada, examined the relationship between chronic obstructive pulmonary disease (COPD) and the risk of CIP in patients treated with ICIs.

Key Takeaways:

  • The study found that 26.6% of patients on ICIs had a pre-existing diagnosis of COPD, with 12.6% of COPD patients experiencing CIP compared to 5.5% of non-COPD patients.
  • The presence of COPD was not statistically associated with an increased risk of CIP, despite a trend suggesting otherwise.
  • Neither FEV1 nor DLCO had a meaningful impact on the development of CIP in COPD patients.
  • The only variable significantly associated with CIP was a poor ECOG performance status, with 19.8% of ECOG 1 patients experiencing CIP compared to 2.2% of those with an ECOG of 0.
  • The study highlights the need for larger prospective studies to confirm these observations and draw definitive clinical recommendations.

Statistics:

  • 327 patients on ICIs were selected for the study, with 23 experiencing an acute respiratory deterioration attributed to CIP.
  • 87 patients (26.6%) had a pre-existing diagnosis of COPD, with 11 (12.6%) experiencing CIP.
  • 240 patients did not have COPD, with 13 (5.5%) experiencing CIP.
  • The study used the Mann-Whitney U test or Fisher's exact test to explore associations between risk factors and CIP.

Sources:

  • NewsRx. Reports Summarize Non-Small Cell Lung Cancer Research from Jewish General Hospital (Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer ...). Respiratory Therapeutics Week. June 9, 2025; p 4466.
  • Spillane, D., et al. (2025). Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?. Current Oncology, 32(5), 259.

Read more